CERS5 and neoplasm: Concentrated adenovirus carrying a Cers5 shRNA vector was administrated to AOM/DSS-treated miR-148a–/– mice (Supplemental Figure 2K), and tumor burden was assessed after mice were sacrificed on day 120 of administration (Supplemental Figure 2K).